WO2020139300A3 - A combination comprising granulocyte colony stimulating factor - Google Patents

A combination comprising granulocyte colony stimulating factor Download PDF

Info

Publication number
WO2020139300A3
WO2020139300A3 PCT/TR2019/051223 TR2019051223W WO2020139300A3 WO 2020139300 A3 WO2020139300 A3 WO 2020139300A3 TR 2019051223 W TR2019051223 W TR 2019051223W WO 2020139300 A3 WO2020139300 A3 WO 2020139300A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
stimulating factor
colony stimulating
granulocyte colony
granulocyte
Prior art date
Application number
PCT/TR2019/051223
Other languages
French (fr)
Other versions
WO2020139300A2 (en
Inventor
Zafer Toksoz
Irem Yenice
Turgay KACAR
Original Assignee
Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arven Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Arven Ilac Sanayi Ve Ticaret Anonim Sirketi
Publication of WO2020139300A2 publication Critical patent/WO2020139300A2/en
Publication of WO2020139300A3 publication Critical patent/WO2020139300A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to a pharmaceutical combination comprising granulocyte-colony stimulating factor (G-CSF) and a biguanide compound for treating a patient with cancer with a targeted therapy in combination with chemotherapies.
PCT/TR2019/051223 2018-12-28 2019-12-26 A combination comprising granulocyte colony stimulating factor WO2020139300A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2018/20952 2018-12-28
TR2018/20952A TR201820952A2 (en) 2018-12-28 2018-12-28 GRANULOCYTE COLONY A COMBINATION WITH A STIMULATING FACTOR

Publications (2)

Publication Number Publication Date
WO2020139300A2 WO2020139300A2 (en) 2020-07-02
WO2020139300A3 true WO2020139300A3 (en) 2020-12-24

Family

ID=71128855

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/051223 WO2020139300A2 (en) 2018-12-28 2019-12-26 A combination comprising granulocyte colony stimulating factor

Country Status (2)

Country Link
TR (1) TR201820952A2 (en)
WO (1) WO2020139300A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093806A1 (en) * 2006-02-17 2007-08-23 Axcess Limited Dissolution aids for oral peptide delivery comprising a biguanide
WO2013012891A1 (en) * 2011-07-19 2013-01-24 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
WO2016140714A1 (en) * 2015-03-05 2016-09-09 The General Hospital Corporation Novel compositions and uses of metformin agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093806A1 (en) * 2006-02-17 2007-08-23 Axcess Limited Dissolution aids for oral peptide delivery comprising a biguanide
WO2013012891A1 (en) * 2011-07-19 2013-01-24 Stc. Unm Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
WO2016140714A1 (en) * 2015-03-05 2016-09-09 The General Hospital Corporation Novel compositions and uses of metformin agents

Also Published As

Publication number Publication date
WO2020139300A2 (en) 2020-07-02
TR201820952A2 (en) 2020-07-21

Similar Documents

Publication Publication Date Title
EP3829595A4 (en) Muscle targeting complexes and uses thereof for treating dystrophinopathies
WO2015181641A3 (en) Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof
TW201613887A (en) Antiproliferative compounds and methods of use thereof
EP3686200A3 (en) Bicyclic heterocycle compounds and their uses in therapy
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
GEP20217286B (en) Pyridone amides as modulators of sodium channels
WO2015051543A8 (en) Cancer treatment with combination of plinabulin and taxane
WO2016025635A3 (en) Combination therapy for treating cancer
WO2017062619A3 (en) Combination therapy for the treatment of cancer
WO2014145642A3 (en) Nrf2 small molecule inhibitors for cancer therapy
CA2908742C (en) Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
WO2014031769A3 (en) Treatment of diseases associated with inflammation
WO2016133903A3 (en) Combination therapy for cancer treatment
PH12020551851A1 (en) Treatment of cancers having driving oncogenic mutations
WO2017062615A3 (en) Combination therapy for the treatment of cancer
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
IL279018A (en) Cancer treatment by blocking host-induced il-1 in combination with radiotherapy
IL276235B1 (en) Use of minaprine to reduce tumor growth
WO2015035410A8 (en) Cancer therapy
WO2020005172A9 (en) Near-infrared (nir) absorbing photosensitizers
WO2010033884A3 (en) Method for the treatment of radiation-induced neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant
WO2015038896A3 (en) Wilforlide a for overcoming chemotherapy resistance
WO2020139300A3 (en) A combination comprising granulocyte colony stimulating factor
PH12018501624A1 (en) A composition comprising pic for treatment of cancer
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19902047

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19902047

Country of ref document: EP

Kind code of ref document: A2